Risultati per: Short Acting Opioid
Questo è quello che abbiamo trovato per te
Tu1686 SPECIFIC SHORT-CHAIN FATTY ACIDS PREVENT CLOSTRIDIOIDES DIFFICILE INFECTION-INDUCED GASTROINTESTINAL DYSFUNCTION IN PRECLINICAL MODEL
367 SHORT- AND LONG-TERM PATENCY AFTER MESOPORTAL VENOUS RECONSTRUCTION DURING PANCREATECTOMY
Tu1105 COST-EFFECTIVENESS OF MONTHLY LONG-ACTING OCTREOTIDE INJECTIONS IN PREVENTING SMALL BOWEL BLEEDING FROM ARTERIOVENOUS MALFORMATIONS
Tu1623 THE DEVELOPMENT OF DE-NOVO MALIGNANCY IN HCV-INFECTED ALLOGRAFTS AFTER LIVER TRANSPLANTATION IN DIRECT-ACTING ANTIVIRAL ERA
1127 NATIONAL TRENDS IN PERIOPERATIVE OPIOID PRESCRIBING FOR AMBULATORY INGUINAL HERNIA REPAIR
Sa1651 HEPATITIS C CURE WITH DIRECT ACTING ANTIVIRALS IN PERSONS WITH HIV LOWERS A METABOLITE-BASED PROGNOSTIC RISK SCORE BUT DOES NOT ALTER PLASMA METABOLITE PROFILES
1043 ROBOTIC PARA-AORTIC LYMPH NODE DISSECTION FOR COLORECTAL CANCER: SHORT-TERM OUTCOMES
Sa1642 TREATMENT WITH DIRECT ACTING ANTIVIRALS DECREASES PROGRESSION OF LIVER FIBROSIS AMONG PATIENTS WITH CHRONIC HEPATITIS C WITHOUT EVIDENCE OF ADVANCED FIBROSIS AT TIME OF TREATMENT
Tu1817 CHANGE FROM REMICADE® TO INFLIXIMAB BIOSIMILAR DOES NOT AFFECT SHORT-TERM OUTCOME IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE.
946 DOES SURGERY FOR IBD DELIVER ON IT'S PROMISES? IMPACT OF SURGERY ON SHORT-TERM PATIENT REPORTED OUTCOMES FROM THE CROHN'S & COLITIS FOUNDATION'S SURGICAL INNOVATIONS, RESEARCH, & QUALITY COLLABORATIVE
843 MINIMALLY INVASIVE SURGERY FOR GASTRIC ADENOCARCINOMA IS ASSOCIATED WITH BETTER SHORT-TERM OUTCOMES WITHOUT COMPROMISE IN LONG TERM AND ONCOLOGICAL OUTCOMES
Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post–2016 CDC Guideline
This retrospective cohort study examines changes in opioid prescribing patterns and health outcomes among patients with sickle cell disease before and after the release of the 2016 US Centers for Disease Control and Prevention (CDC) opioid guideline.
What is the ideal time to begin tapering opioid agonist treatment? A protocol for a retrospective population-based comparative effectiveness study in British Columbia, Canada
Introduction
Opioid agonist treatment (OAT) tapering involves a gradual reduction in daily medication dose to ultimately reach a state of opioid abstinence. Due to the high risk of relapse and overdose after tapering, this practice is not recommended by clinical guidelines, however, clients may still request to taper off medication. The ideal time to initiate an OAT taper is not known. However, ethically, taper plans should acknowledge clients’ preferences and autonomy but apply principles of shared informed decision-making regarding safety and efficacy. Linked population-level data capturing real-world tapering practices provide a valuable opportunity to improve existing evidence on when to contemplate starting an OAT taper. Our objective is to determine the comparative effectiveness of alternative times from OAT initiation at which a taper can be initiated, with a primary outcome of taper completion, as observed in clinical practice in British Columbia (BC), Canada.
Methods and analysis
We propose a population-level retrospective observational study with a linkage of eight provincial health administrative databases in BC, Canada (01 January 2010 to 17 March 2020). Our primary outcomes include taper completion and all-cause mortality during treatment. We propose a ‘per-protocol’ target trial to compare different durations to taper initiation on the likelihood of taper completion. A range of sensitivity analyses will be used to assess the heterogeneity and robustness of the results including assessment of effectiveness and safety.
Ethics and dissemination
The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Results will be disseminated to local advocacy groups and decision-makers, national and international clinical guideline developers, presented at international conferences and published in peer-reviewed journals electronically and in print.
Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment
Introduction
Cabotegravir long-acting injectable HIV pre-exposure prophylaxis (LA-PrEP) was shown to be safe and effective in multiple clinical trials. Increasing uptake and persistence among populations with elevated risk for HIV acquisition, especially among men who have sex with men (MSM), is critical to HIV prevention.
Objective
This analysis aims to understand potential users’ preferences for LA-PrEP, with audience segmentation.
Design
Willingness to use and preferences for LA-PrEP were measured in HIV-negative, sexually active MSM in the 2020 American Men’s Internet Survey. Respondents answered a discrete choice experiment with paired profiles of hypothetical LA-PrEP characteristics with an opt-out option (no LA-PrEP). Conditional and mixed logit models were run; the final model was a dummy-coded mixed logit that interacted with the opt-out.
Setting
US national online sample.
Results
Among 2506 MSM respondents, most (75%) indicated a willingness to use LA-PrEP versus daily oral PrEP versus no PrEP. Respondents were averse to side effects and increasing costs and preferred increasing levels of protection. Respondents preferred a 2-hour time to obtain LA-PrEP vs 1 hour, with a strong aversion to 3 hours. Overall, there was an aversion to opting out of LA-PrEP, with variations: those with only one partner, no/other insurance or who were Black, Indigenous or People of Colour were significantly less likely to prefer LA-PrEP, while those who were Hispanic/Latino, college educated and
Integrated Hepatitis C–Opioid Use Disorder Care Through Telemedicine
This study discusses whether facilitated telemedicine for hepatitis C treatment increases cure rates compared with standard-of-care referral to hepatitis specialists.